AMG National Trust Bank Invests $3.71 Million in IQVIA Holdings Inc. $IQV

AMG National Trust Bank purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,549 shares of the medical research company’s stock, valued at approximately $3,713,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its stake in shares of IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after acquiring an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in IQVIA in the 2nd quarter valued at approximately $515,772,000. JPMorgan Chase & Co. boosted its position in IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after purchasing an additional 581,157 shares in the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares during the last quarter. Finally, Cantillon Capital Management LLC increased its position in shares of IQVIA by 27.3% in the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock valued at $366,002,000 after buying an additional 413,256 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th. UBS Group dropped their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Citigroup reduced their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $235.20.

IQVIA Trading Down 2.2%

NYSE IQV opened at $165.63 on Friday. The firm has a market capitalization of $28.11 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 1.63 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company’s 50 day moving average price is $217.61 and its 200 day moving average price is $208.27.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.